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Background: Shoulder pain is a very common presentation in primary care. Evidence of benefit for subacromial
corticosteroid injection is inconclusive and confined largely to studies with short follow-up. We plan a large,
definitive, primary-care-based trial to determine efficacy and safety in patients with rotator cuff tendinopathy,
and conducted a pilot trial to explore feasibility.
Methods: Six general practitioners (GPs) from Oxfordshire, UK underwent update training in assessing painful
shoulders and injecting the subacromial space. Each then recruited patients aged 35 to 74 years from primary care
complaining of shoulder pain lasting no more than 6 months. Eligible participants were randomized to receive
either methylprednisolone acetate 40 mg with lidocaine 1% (total volume 1 ml), or lidocaine 1% alone (total
volume 1 ml), injected into the subacromial space. The participants were blinded to treatment allocation. Feasibility
outcomes were rates of recruitment, withdrawal, adherence to the protocol, completeness of follow-up, and success
of patient masking. Clinical outcomes were the Oxford Shoulder Score (OSS) at baseline and at 4 and 12 weeks,
and responses to three satisfaction questions at 2, 4 and 12 weeks. Outcome data were collected by postal
questionnaires.
Results: A total of 40 participants were randomized (80% of the target 50 participants) over 26 weeks giving an
overall recruitment rate of 1.5 participants per week. Rates of follow-up were maintained to a high level for the full
12 weeks. Four participants requested a ‘rescue’ corticosteroid injection but no patients withdrew. The trial GPs
gave high scores for their confidence that the patient had remained blinded to treatment allocation during the
procedure. The OSS at 4 and 12 weeks and the responses to the satisfaction questions are reported.
Conclusions: It is feasible to recruit participants with shoulder pain in the primary care setting for a blinded,
randomized trial of corticosteroid injection. Online randomization of participants from the practice is also feasible,
and postal questionnaires provide an effective means of gathering outcome data in this area of study. The lessons
learned from this pilot will usefully inform the design of a large, definitive efficacy trial in primary care.
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Shoulder pain is a common complaint with prevalence
in the community of around 16% [1]. Shoulder pain can
result from a number of underlying disorders including
rotator cuff tendinopathy, adhesive capsulitis (‘frozen
shoulder’) and osteoarthritis. These conditions may be
disabling and carry a significant economic cost [2].
Painful shoulders can be managed in a variety of ways,
including analgesia, non-steroidal anti-inflammatory drugs,
physiotherapy, and corticosteroid injection [3]. Response to
these treatments is unpredictable, and 40% to 50% of
patients still have pain at 6 months [4-6]. A significant
minority suffers persistent pain and functional impairment
[7]. A small proportion requires further investigation and
surgical intervention, but this is usually reserved for those
failing to respond to conservative therapies.
Corticosteroid injections are widely used in primary
care to treat shoulder pain. There is a mixed evidence
base to support this treatment and trial results have
been inconsistent since the 1980s. Some studies have
included all painful shoulder problems, while others
investigated patients with a specific underlying diagnosis.
A systematic review in 1996 found few studies of
adequate methodological quality and evidence for effi-
cacy was scarce [8]. In a subsequent Cochrane review
published in 2003 there appeared to be a small benefit
of subacromial injection versus placebo for rotator cuff
tendinopathy but the authors concluded that the effect
may be small and not well maintained [9]. Further
research was recommended. A meta-analysis in 2005
suggested benefit of subacromial injection for rotator
cuff tendinitis but half of the eight included studies were
of low methodological quality [10]. In all cases, the trial
injections were delivered by an orthopedic surgeon,
rheumatologist, internal medicine specialist or rehabili-
tation specialist rather than a general practitioner (GP).
The UK primary-care-based SAPPHIRE trial used a
factorial design to investigate the effect both of training
GPs in treating shoulder problems and of corticosteroid
injection versus lidocaine local anesthetic (LA) injection
[11]. It found GP training to be cost effective, but the
cost effectiveness of corticosteroid over lidocaine was
inconclusive [12].
A 2010 systematic review by Coombes et al. of both cor-
ticosteroid and non-corticosteroid injections for various
tendinopathies concluded that corticosteroid injections
for lateral epicondylalgia of the elbow (‘tennis elbow’)
are limited in their efficacy to a short-term response
(4 weeks, range 0 to 12) [13]. For follow-up at inter-
mediate (26 weeks, range 13 to 26) and longer term
(52 weeks, range ≥52), outcomes were worse than for
no treatment. This review questioned the basis for a
very commonly used intervention. The short-term ef-
ficacy of corticosteroids for rotator cuff tendinopathywas reported as unclear. It is not possible on current
evidence to exclude a clinically meaningful adverse
effect of corticosteroid injection on shoulder pain and
function following subacromial injection, particularly
over intermediate and longer timescales.
A large-scale, primary-care-based trial of corticosteroid
injection for rotator cuff tendinopathy is required. To en-
sure the success, quality and reliability of such a trial, a
number of feasibility questions need to be answered. Prin-
cipally these concern the acceptability of the trial concept
and design to patients and healthcare professionals, and
the rates of recruitment and adherence to the protocol, all
of which are crucial factors to success. A number of stud-
ies have investigated corticosteroid injection for shoulder
pain and have recruited successfully in the primary care
setting. For instance, Hay et al. compared corticosteroid
injection with physiotherapy [14], and Crawshaw et al.
compared corticosteroid injection plus exercise with exer-
cise alone [15]. However, we required participants to
accept blinded randomization to receive a subacromial in-
jection that might or might not contain corticosteroid and
in which the comparator was unlikely to have more than a
very short-term effect. The acceptability of this design was
therefore important to establish.
Our focus of interest in this pilot study, following the
Coombes et al. systematic review [13], is rotator cuff
tendinopathy rather than adhesive capsulitis. However in
general practice the distinction between these conditions
is not always obvious and it is known that GPs often
adopt a pragmatic approach using non-specific ‘shoulder
pain’ codes rather than specific coded diagnoses in the
record [16]. A further aim of this feasibility study was
therefore to determine how easily these two conditions




This is a single-blind, randomized controlled pilot trial
in primary care. General practitioners working at six
practices in Oxfordshire, UK were recruited and under-
took update training by an orthopedic shoulder surgeon
in assessing painful shoulders and injecting the suba-
cromial space. Patients presenting with shoulder pain to
any clinician in these general practices were asked if they
would be willing to participate.
Participants
Adult patients aged 35 to 74 years with a clinical diagno-
sis of rotator cuff tendinopathy or adhesive capsulitis.
Inclusion criteria
Inclusion criteria are: (1) male or female, aged 35 to
74 years; (2) diagnosis of rotator cuff tendinopathy or
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shoulder assessment, with duration of symptoms no
greater than 6 months; (3) willing to allow his or her
usual GP to be notified of participation in the study and
to be contacted for further information if an adverse
event related to the trial occurs; (4) able to complete
follow-up data collection by questionnaire at 2, 4, and
12 weeks; and (5) willing and able to give informed
consent for participation in the trial.
Exclusion criteria
Exclusion criteria are: (1) female participants who are
pregnant, lactating or planning pregnancy during the
course of the study; (2) participants who have participated
in another research study involving an investigational
product in the past 12 weeks; (3) those having already
received a shoulder injection in the past 12 months; (4)
those with other established chronic shoulder disorders
(for example, rheumatoid arthritis, other inflammatory
polyarthropathies and osteoarthritis); (5) a history of
previous shoulder surgery on the affected side; (6) those
with evidence of active infection anywhere, including
temperature >37.5°C; (7) those currently prescribed anti-
coagulants; (8) those either currently prescribed, or likely
to need during the following 12 months, systemic cortico-
steroids for any reason; (9) immunocompromised patients;
(10) uncontrolled diabetes or uncontrolled hypertension;
(11) a diagnosis of heart failure; (12) those considered
unable due to cognitive impairment to reliably report
outcome measures; (13) any other significant disease or
disorder which, in the opinion of the general practitioner,
may either put the participants at risk because of partici-
pation in the study, or may influence the participant’s
ability to participate in the study; and (14) any patient
who is allergic to corticosteroids and/or lidocaine.
Recruitment
GPs interested in participating in the study were identi-
fied from practices within the Oxfordshire region. One
GP in each of six recruiting practices was identified as
the ‘trial GP’. Prior to recruitment of participants, trial
GPs underwent study specific training in the assessment
of shoulder pain, including the distinction of rotator cuff
tendinopathy from adhesive capsulitis and the distinc-
tion of these two conditions and other disorders not
relevant to this study. They also received training on the
injection technique into the subacromial space employed
in this trial. Training was led by an academic orthopedic
shoulder surgeon from the Nuffield Orthopaedic Centre
at Oxford and is based on the British Elbow and Shoul-
der Society (BESS) Pathway Guideline for Sub-acromial
Pain [17]. The trial GPs also received study specific good
clinical practice (GCP) training and training in the
study procedures (for example, case report form (CRF)completion, safety reporting) from the Primary Care
Clinical Trials Unit. The training took less than 1 day to
complete.
Potential participants were identified presenting to pri-
mary care complaining of shoulder pain. They were given
information about the study and if willing to take part in
the trial asked to make a 60-minute appointment with the
participating trial GP at that GP practice, (not necessarily
their usual GP) no earlier than the following day after
invitation. This provided the opportunity to read the infor-
mation and make a decision over participation.
Screening and baseline assessment
During the 60-minute appointment, a screening form
was completed by the trial GP to confirm eligibility.
Brief, anonymized demographic information (age, gender,
self-declared ethnicity) was collected for all patients
screened and blood pressure and temperature measure-
ments were taken. If the person was ineligible, the trial GP
discussed clinical management of the shoulder problem
with the patient and arranged appropriate care outside the
trial. If the participant was eligible, the trial GP then con-
ducted the consent process using the Consent Form. A
baseline measure of the OSS was made, and other baseline
data collected on a Baseline Assessment Form, including:
shoulder symptoms (location, presence of arm pain, neck
pain, shoulder stiffness, duration of symptoms, suspected
triggers (for example, overuse/strain)); clinical findings,
including range of lateral rotation of the glenohumeral
joint (limitation might be due to either pain or stiffness);
medical history (presence of physical disability, vascular
disease, diabetes, hypertension); and concomitant medica-
tion (all prescribed medication was recorded on the CRF
as well as ‘over-the-counter’ medication for the shoulder
problem itself ).
Randomization
The trial GP obtained a randomization allocation online
from the Primary Care - Clinical Trials Unit (PC-CTU)
at Oxford University. Randomization occurred only after
consent to injection on that same day had been ob-
tained. Varying block sizes of 2 or 4 were used with 1:1
allocation to methylprednisolone acetate with lidocaine
or lidocaine alone.
Interventions
The trial injection (methylprednisolone acetate 40 mg
with lidocaine 1% in 1 ml, or lidocaine 1% in 1 ml alone)
was given according to the randomized allocation by
injection into the subacromial space.
The vials were sourced and labeled by Almac Clinical
Services Ltd (Almac House, 20 Seagoe Industrial Estate,
Craigavon, BT63 5QD, UK) and stored according to

















Figure 1 Cumulative recruitment during the 26 weeks of the trial.







1 26 12 0.5
2 26 4 0.15
3 24 8 0.3
4 23 4 0.2
5 24 6 0.25
6 5 6 1.2
Overall 26 40 1.5
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oid suspension (compared with the clear appearance of
the lidocaine alone) it was not in practice possible to mask
the trial GP to the treatment allocation. Every effort was
made to ensure that the participants remained masked
throughout the procedure. This was made easier as the
injection was through a posterior approach. The allocation
was not written in the health record and the other GPs in
the practice (which in many cases included the ‘usual con-
sulting GP’) were therefore also unaware of the allocation.
Primary outcome measures
Primary outcome measures are: proportion of screened
patients eligible to enter the study, proportion of eligible
patients willing to provide consent, rates of recruitment
(patients per practice per week), loss to follow-up inclu-
ding withdrawal from the trial, and adherence to the
allocated treatment.
Secondary outcome measures
Secondary outcome measures are Oxford Shoulder
Score (OSS) [18] at 4 and 12 weeks following injection,
and responses to three satisfaction questions at 2, 4 and
12 weeks post injection: (1) ‘How are the problems
related to your shoulder NOW, compared with before
your shoulder injection?’ (possible responses: no problems
at all now; much better; slightly better; no change; slightly
worse; much worse), (2) ‘Overall, how pleased have you
been with the result of your shoulder injection?’ (possible
responses: very pleased; fairly pleased; not very pleased;
very disappointed), and (3) ‘If you could go back in time,
would you still choose to have the shoulder injection?’
(possible responses: yes; no; not sure).
The OSS refers to the symptom pattern and shoulder
function over the preceding 4 weeks. It was not there-
fore meaningful to measure this at the 2-week follow-up
interval. The OSS has been found to have good sensitiv-
ity, validity and responsiveness (ability to detect import-
ant changes over time) [19] as well as a high postal
return rate [20].
Outcome data collection
The trial GPs returned screening/eligibility assessment
forms and baseline questionnaires, yielding data on re-
cruitment rates and the proportions of screened patients
found to be eligible, eligible participants consented, and
consented participants randomized. The participants
were handed a follow-up questionnaire to complete at
2 weeks following the injection. Subsequent follow-up
questionnaires (at 4 weeks and 12 weeks) were sent by
post a week before the due date. The participants were
reminded by telephone, text or email (according to their
stated preference) the day before the assessment was
due, if they were willing to receive such reminders. If theform was not received by the research team by 4 days
after this due date, a maximum of two non-optional
reminders were issued via telephone, text or email. Their
wording was as follows: ‘This is a reminder that your
follow-up shoulder assessment is due on (date). Please
complete the questionnaire and return it to the Research
team in the FREEPOST envelope. Thank you’.
Information on other treatments for the shoulder
pain (for example, physiotherapy, prescribed or ‘over-
the-counter’ analgesia, non-steroidal anti-inflammatory
drugs, rescue injection) was also gathered using the
questionnaire.
After 12 weeks, the participant’s medical records
were reviewed by either the trial GP or the patient’s
usual GP, to provide information on other treatments
the participant may have received for their shoulder
but not mentioned on the questionnaire. Such other
treatments might include a ‘rescue’ injection, that is,
a definite corticosteroid injection given at the partici-
pant’s request before the end of the 12-week study
follow-up. Such a treatment represented a protocol
deviation but the participant remained in the trial
unless they declined follow-up and requested no further
contact with the research team.
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To further inform feasibility we measured the subjective
confidence of the trial GP that the participant had
remained blind to treatment allocation during the pro-
cedure, on a scale of 0% (certain that the allocation had
been revealed) to 100% (certain that the participant
remained unaware). We gathered feedback from GPs onScreened fo
Ran
(
Allocated to Methylprednisolone 

















* Includes one participant who did not return a 4 we
Figure 2 Flow diagram of trial participants.the adequacy of informational materials and other docu-
mentation to support the trial.
Statistical analysis plan
Descriptive data are presented for all feasibility and
clinical outcomes. We derived confidence intervals for
difference between trial arms in change from baseline inr eligibility (n= 49)
domised
n=40)
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Table 2 Baseline characteristics of randomized participants
Characteristic Methylprednisolone
acetate with
lidocaine (n = 19)
Lidocaine
(n = 21)
Female, n (%) 11 (58%) 15 (71%)
Age at randomization in years,
mean (SD)
61.5 (5.8) 56.0 (11.3)
Ethnic group:
White 19 (100%) 19(90%)
Bangladesh/Indian 0 2 (10%)
Have major medical history 9 (47%) 9 (43%)
Right/left handed:
Right 18 (95%) 18 (86%)
Left 1 (5%) 3 (14%)
Which shoulder affected:
Right 13 (68%) 12 (57%)
Left 6 (32%) 9 (43%)
History of trigger for the
shoulder pain
5 (26%) 6 (29%)
Current medication for shoulder
problem:
Painkillers 11 (58%) 11 (52%)
Anti-inflammatory medication 12 (63%) 11 (52%)
Physiotherapy 3 (16%) 5 (24%)
Other
Shoulder stiffness addition to
shoulder pain
9 (47%) 12 (57%)
Arm pain addition to shoulder pain 17 (89%) 19 (90%)
Neck pain addition to shoulder pain 9 (47%) 7 (33%)
Other symptoms addition to
shoulder pain
6 (32%) 6 (29%)
Duration of any symptom in this
shoulder for this episode (weeks),
mean (SD)
15.9 (6.1) 10.7 (5.0)
History of shoulder pain 5 (26%) 6 (29%)
Systolic blood pressure, mmHg 130 (14.4) 133 (22.4)
Diastolic blood pressure, mmHg 80 (11.2) 77 (14.7)
Body temperature in °C, mean (SD) 36.7 (0.43) 36.7 (0.44)
Rotation of the glenohumeral joint
compared to other side:
Greater that 50% 17 (89%) 17 (81%)
Less than 50% 2 (11%) 4 (19%)
Table 3 Rates of completion of outcome data collection
Baseline 2 Weeks 4 Weeks 12 Weeks
40% 40% 39% 38%
100% 100% 97.5% 95%
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adjusting for OSS at baseline.
Ethical approval and consent
The study was approved by NRES Committee South
Central, Oxford B, Bristol REC Centre, Ref: 12/SC/0233,
EudraCT number: 2012-000147-27.
Consent was obtained from participants prior to
randomization for the following: receipt of the trial
injection, forwarding of contact details to the research
team, willingness to receive up to two reminders in the
event of delay in returning outcome data, and exami-
nation of medical records by a GP for the 12 weeks
following the trial injection.
Results and discussion
The pilot ran for 26 weeks during which no serious ad-
verse events were reported. Table 1 gives the recruit-
ment rate by practice from the date of the first site
initiation and Figure 1 the cumulative recruitment from
the date of first patient recruited. Of 49 screened partici-
pants, 42 were deemed eligible, and of these 2 declined
to participate (Figure 2). Of the remaining seven, two
were found to have shoulder conditions other than rota-
tor cuff tendinopathy or adhesive capsulitis; two had a
temperature >37.5°C; one was less than 35 years old; one
had a diagnosis of heart failure; and one was taking an
oral anticoagulant. All consented participants were ran-
domized and received the trial injection. Recruitment
took longer than anticipated but 80% of the planned
sample of 50 participants was achieved by study comple-
tion. It was clear that trial GPs required the awareness
of their GP partners to identify potential participants to
be referred into the study. The sixth GP was brought in
towards the end of the study to improve recruitment
rates and this move proved successful. The background
population of all registered patients was 63,663, out of
which 31,249 were aged 35 to 74 years.
There were no difficulties reported with administering
the trial injection. GP confidence that the patient had
remained unaware of the allocation was reported as
100% in 28/40 cases and 80% to 99% in the remaining
12/40 cases, with no significant difference between the
trial arms. While we considered this to be satisfactory,
we intend to explore the possibility of blinding the trial
GPs in the main trial using opaque syringes. This may in
practice be difficult as even a small drop of fluid appear-
ing at the needle tip could reveal the allocation. We
minimized awareness of allocation in this pilot by ensur-
ing that no clinician other than the GP administering
the injection was aware. The allocation was recorded
separately from the patients’ electronic records and was
therefore not visible to the wider clinical team. All of
our clinical outcomes were patient reported.
Table 4 Adherence to the allocated treatment
Category Methylprednisolone
acetate with




No. (%) adhering to
allocated treatment
18 (95%) 18 (86%) 0.607
aFisher’s exact test.
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similar between the trial arms. Six participants (15% of
study sample) had less than 50% range of lateral rotation
of the glenohumeral joint compared with the unaffected
side, suggesting a clinical diagnosis of adhesive capsulitis.
It was unclear at the outset exactly what proportion of
participants would be in this subgroup and whether
from a practical point of view their identification would
be possible, given the known uncertainty associated with
primary care diagnosis of shoulder pain. The GPs did
not report any difficulty applying this decision rule and
the pilot suggests that this subgroup is clinically distin-
guishable on this basis in this setting. It will therefore be
possible to exclude those with adhesive capsulitis at the
screening stage from a future larger trial where the main
focus of interest is on rotator cuff tendinopathy.
Table 3 reports the rates of completion of outcome
data collection by postal questionnaire, indicating that
this is an effective means of gathering such data in this
area of study. Postal questionnaires were received by the
PC-CTU on average 4.12 days after the due date
(±4.11 days) (2 week questionnaire 3.9 days (±2.9);
4-week questionnaire at 4.8 days (±4.2); 12-week
questionnaire at 3.7 (±4.9). A total of 38 non-optional
reminders were sent to participants. At 2 weeks a total of
6 reminders were sent, 10 reminders were sent for the
return of 4-week questionnaires and 22 reminders were
required for the return of the 12-week questionnaires. The
need for a second reminder also increased with time.
Table 4 presents the adherence to the allocated treat-
ment during the study. One participant in the group
allocated to methylprednisolone acetate with lidocaine
and three in the lidocaine alone group requested a
‘rescue’ corticosteroid injection during the 12-weekTable 5 Oxford shoulder scorea
Stage Methylprednisolone acetat
with lidocaine (n = 19)
Baseline 26.4 (7.4)
4 weeks 30.3 (10.5)
12 weeks 30.6 (10.8)
Change at 4 weeks from baseline 3.9 (8.5)
Change at 12 weeks from baseline 4.2 (9.1)
aThe higher the score the better.
bn = 21 at baseline and 19 from 4 weeks onwards.
cAdjusted for baseline score.follow-up. This result is not significant based on these
small numbers, but we recognize the potential for lack
of blinding of the trial GP to influence this outcome.
Table 5 gives the OSS outcomes by trial arm. We have
derived confidence intervals for the difference between
the arms but recognize that the standard deviation (SD)
derived in a pilot study such of this may not be a reliable
estimate of the SD in real-world practice or in a larger trial
[21]. A rise in the OSS score (indicating improvement)
was seen in both arms at 4 and 12 weeks compared to
baseline, as might be expected. The rise in the lidocaine
alone arm was greater than that of the active injection but
the difference was not statistically significant in this pilot
study. Nevertheless, this result justifies further inves-
tigation through a large definitive trial powered to detect
such a difference.
Figures 3A-C and Table 6 present the response rates
to the satisfaction question options in each arm. There
is a suggestion of improved satisfaction in the methyl-
prednisolone acetate with lidocaine arm at the 2-week
interval compared with lidocaine alone.
Finally, Table 7 reports the other treatments received
by the trial participants during the study.
Conclusions
We succeeded in enrolling 40 participants with shoulder
pain in the primary care setting for a blinded, randomized
pilot trial of corticosteroid injection. Experience of work-
ing with the practices suggested that whole practice
involvement in case identification is important to optimize
recruitment. Online randomization of participants from
the practice supported the single-blinded approach used
in this study. Postal questionnaires proved effective for
outcome data collection when supported by text or email
reminders. The lessons learned from this pilot will usefully
inform the design of a large, definitive efficacy trial in pri-
mary care. It will be important to optimize recruitment
and maintain a high rate of follow-up over 52 weeks in
the larger, main trial that we plan. Such a trial is necessary
to confirm the benefits of corticosteroid injection, a com-
monly used treatment for shoulder pain, and to exclude
adverse longer-term outcomes.e Lidocaineb Estimated difference in change




6.3 (10.1) −2.4 (−8.1 to 3.4)
8.2 (11.3) −2.9 (−9.0 to 3.2)
Figure 3 Responses by trial arm to the three satisfaction questions (MP = methylprednisolone acetate, LA = local anaesthetic). A: How
are the problems with your shoulder NOW compared with before the injection?. B: Overall, how pleased have you been with the result of your
shoulder injection?. C: If you could go back in time, would you still choose to have the shoulder injection?
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Table 6 Satisfaction with injection
Criteria Methylprednisolone acetate






No problems at all 1 (5%) 1 (5%)
Much better 1 (5%) 2 (10%)
Slightly better 10 (53%) 4 (19%)
No change 3 (16%) 5 (24%)
Slightly worse 3 (16%) 7 (33%)




No problems at all 1 (5%) 2 (10%)
Much better 5 (26%) 3 (15%)
Slightly better 4 (21%) 5 (25%)
No change 6 (32%) 7 (35%)
Slightly worse 1 (5%) 2 (10%)





No problems at all 1 (5%) 1 (5%)
Much better 5 (26%) 8 (42%)
Slightly better 3 (16%) 3 (16%)
No change 8 (42%) 3 (16%)
Slightly worse 2 (11%) 0 (0%)





Very pleased 1 (5%) 2 (10%)
Fairly pleased 9 (47%) 3 (14%)
Not very pleased 5 (26%) 9 (43%)
Very disappointed 4 (21%) 7 (33%)
Responses to second
satisfaction question at 4
weeks:
Very pleased 4 (24%) 3 (15%)
Fairly pleased 4 (24%) 4 (20%)
Not very pleased 3 (18%) 6 (30%)
Very disappointed 6 (35%) 7 (35%)
Data missing 1




Very pleased 4 (21%) 4 (21%)
Fairly pleased 5 (26%) 5 (26%)
Not very pleased 2 (11%) 5 (26%)





No 2 (10%) 4 (19%)
Yes 14 (74%) 10 (48%)




No 4 (21%) 5 (25%)
Yes 14 (74%) 11 (55%)





No 3 (16%) 5 (26%)
Yes 12 (63%) 10 (53%)
Not sure 4 (21%) 4 (21%)
Data missing 2









Painkillers 8/18 (44%) 11/21 (52%)
Anti-inflammatory
medication
5/18 (28%) 10/20 (50%)
Physiotherapy 0/17 (0%) 1/20 (5%)
At 4 weeks:
Painkillers 7/19 (37%) 11/20 (55%)
Anti-inflammatory
medication
4/17 (24%) 7/19 (37%)
Physiotherapy 1/16 (6%) 3/19 (16%)
At 12 weeks:
Painkillers 7/17 (41%) 11/19 (58%)
Anti-inflammatory
medication
6/19 (32%) 10/16 (63%)
Physiotherapy 1/18 (6%) 6/18 (33%)
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